---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-003285"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:11:06.638294+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ATAI acquires additional ~11.2M shares in Beckley Psytech for $10M, raising stake to 35.47%

## Summary
- Secondary purchase of 11,153,246 shares from existing shareholders at ~$0.8966/share, total $10M.
- Combined with Jan 3 primary investment of $40M for 24.1M Series C shares, total outlay ~$50M.
- ATAI now holds a 35.47% voting interest in Beckley Psytech Limited.
- All acquired shares re-designated as Series C preferred shares; investment closed on Jan 18, 2024.
- Transaction structured via Share Purchase Deed; warrants customary representations from sellers.

## SEC filing metadata
- accession: 0001140361-24-003285
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036124003285/0001140361-24-003285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036124003285/ef20019485_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-003285
- JSON: https://secwatch.observer/filing/0001140361-24-003285.json
- Plain text: https://secwatch.observer/filing/0001140361-24-003285.txt

## Key facts
- M&A Transactions
  ATAI Life Sciences N.V. completed an acquisition involving Beckley Psytech Limited for total purchase price of US $10,000,000.37 (closed 2024-01-18).
  - Action: acquisition
  - Counterparty: Beckley Psytech Limited
  - Consideration: total purchase price of US $10,000,000.37
  - Closing: 2024-01-18
  source text: On January 18, 2024, pursuant to the SSA, the Company entered into a Share Purchase Deed (the “Secondary Sale SPA”), pursuant to which the Company acquired a total of 11,153,246 additional shares of BPL from certain existing shareholders of BPL, for a total purchase price of US $10,000,000.37
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124003285/0001140361-24-003285-index.htm
- Material Agreements
  ATAI Life Sciences N.V. entered into subscription and shareholders’ agreement with Beckley Psytech Limited and certain other shareholders valued at $39,999,999.10 (effective 2024-01-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Beckley Psytech Limited and certain other shareholders
  - Value: $39,999,999.10
  - Effective: 2024-01-03
  source text: on January 3, 2024, atai Life Sciences N.V. (the “Company”) entered into that certain subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL, as identified in such agreement (the “SSA”), under which, among other things, the Company acquired 24,096,385 newly issued series C preferred shares, par value £0.0001 per share, of BPL (the “Series C Shares”) for a total purchase price of $39,999,999.10
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124003285/0001140361-24-003285-index.htm
- Material Agreements
  ATAI Life Sciences N.V. entered into Share Purchase Deed with certain existing shareholders of BPL valued at $10,000,000.37 (effective 2024-01-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain existing shareholders of BPL
  - Value: $10,000,000.37
  - Effective: 2024-01-18
  source text: On January 18, 2024, pursuant to the SSA, the Company entered into a Share Purchase Deed (the “Secondary Sale SPA”), pursuant to which the Company acquired a total of 11,153,246 additional shares of BPL from certain existing shareholders of BPL, for a total purchase price of US $10,000,000.37
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124003285/0001140361-24-003285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.